User:Joanna Morelli/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
==Facilitated Glucose Transporter 3, Solute Carrier Family 2 (GLUT3/ SLC2A3) in Homo Sapiens==
+
=Insulin Glargine=
-
<StructureSection load='5c65' size='340' side='right' caption='Human glucose transporter complex with cholesterol derivative (PDB code [[5c65]])'>
+
<StructureSection load='4iyd' size='340' side='right' caption='Caption for the 3D structure blah blah' scene=''>
-
== Function ==
+
-
GLUT3 is one of fourteen facilitative sugar transporters, which use the glucose diffusion gradient to move across various plasma membranes to display various specificities, kinetics and tissue expression profiles <ref name="three">Long, W., & Cheeseman, C. I. (2015). Structure of, and functional insight into the GLUT family of membrane transporters. Cell Health and Cytoskeleton, 7, 167-183. doi:10.2147/CHC.S60484</ref>. Glucose transporters are approximately 500 amino acids in length and part of a growing superfamily of integral membrane glycoproteins that have 12 transmembrane (TM) helices. The transmembrane regions presumably create channels through which glucose can move<ref name="four">Kipmen-Korgun, D., Bilmen-Sarikcioglu, S., Altunbas, H., Demir, R., & Korgun, E. T. (2009). Type-2 diabetes down-regulates glucose transporter proteins and genes of the human blood leukocytes.Scandinavian Journal of Clinical and Laboratory Investigation, 69(3), 350-358.
+
-
doi:10.1080/00365510802632163</ref>. GLUT3 is categorized as a Class I transporter due to its protein sequence and structural similarity to other glucose transporters grouped in Class I<ref name="three"/>. GLUT3 displays the highest affinity for glucose of all of the Class I glucose transporters and has a transport capacity five times greater than that of GLUT1 and GLUT4<ref name="five"> Simpson,I. A., Dwyer, D., Malide, D., Moley, K. H., Travis, A., & Vannucci, S. J. (2008). The facilitative glucose transporter GLUT3: 20 years of distinction. American Journal of Physiology - Endocrinology and Metabolism, 295(2), E242-E253. doi:10.1152/ajpendo.90388.2008</ref>. In humans, GLUT3 is found predominantly in brain tissue, highly and specifically expressed by neurons, and has some expression in peripheral tissues. For this reason GLUT3 is commonly known as the “neuronal glucose transporter”<ref name="five"/><ref name="six">Maher, F., Vannucci, S. J., & Simpson, I. A. (1994). Glucose transporter proteins in brain. FASEB Journal, 8(13), 1003-1011.</ref>. GLUT3 has a more restricted expression pathway, which represents specialized functions for the protein<ref name="seven">Xu, J., Lu, C., Wang, J., Zhang, R., Qian, X., & Zhu, H. (2015). Regulation of human trophoblast GLUT3 glucose transporter by mammalian target of rapamycin signaling. International Journal of Molecular Sciences, 16(6), 13815-13828. doi:10.3390/ijms160613815</ref>. GLUT3 has been found to play an important role in gestational development and maintaining the brain's structure. Defects in GLUT3 can cause fetal death as well as neurodegeneration, which can lead to diseases like Alzheimer’s<ref name="eight">Liu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I., & Gong, C. -. (2008). Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in alzheimer disease. FEBS Letters, 582(2), 359-364. doi:10.1016/j.febslet.2007.12.035</ref>.
+
-
==Structure==
+
== Manufacture ==
-
GLUT3(<scene name='71/716527/5c65/1'>5c65</scene>) is a transport protein consisting of 481 amino acids and weighing 52,520 Daltons in its asymmetrical unit<ref name="nineteen">http://www.ebi.ac.uk/pdbe/entry/pdb/5c65/</ref>. This protein is an alpha-helical protein consisting of two chains, two different ligands and water<ref name="nineteen"/>. The structure was determined by X-Ray diffraction and was measured at a resolution of 2.65 Angstroms<ref name="twentytwo">http://oca.weizmann.ac.il/oca-bin/ocaids?id=5c65</ref>. GLUT3 consists of 12 transmembrane segments (TMs) folded “into the N-terminal and C-terminal domains, each comprising ‘3+3’ inverted repeats”<ref name="nine"/> These TMs consist of four 3 repeated sections. [http://www.nature.com/nature/journal/v526/n7573/fig_tab/nature14655_F1.html Here] is a figure by Deng, D., et al. showing these repeated transmembrane segments<ref name="nine">Deng, D., Sun, P., Yan, C., Ke, M., Jiang, X., Xiong, L., . . . Yan, N. (2015). Molecular basis of ligand recognition and transport by glucose transporters. Nature, 526(7573), 391-396. doi:10.1038/nature14655</ref>. The protein consists of two different ligands, Y01 and 37X<ref name="eighteen">http://www.rcsb.org/pdb/explore.do?structureId=5C65</ref>. Octyl Glucose Neopentyl Glycol (<scene name='71/716528/37x/2'>37X</scene>) has a chemical formula of C<sub>27</sub>H<sub>52</sub>O<sub>12</sub> and a molecular weight of 569 Da. There are six 37X (501-506a) bound to chain A of 5c65. These ligands are kept in place by hydrogen bonds to arginine, proline, and serine and by van der Waals forces. Chain B has three 37X ligands attached to it (501-503b). These are attached through hydrogen bonds by arginine, proline, and serine as well as by van der Waals forces<ref name="twenty">http://www.ebi.ac.uk/pdbe/entry/pdb/5c65/bound/37X</ref>. To view 37X in 3D use [http://www.rcsb.org/pdb/explore/jmol”.do?structureId=5C65&residueNr=37X JSmol]. Cholesterol hemisuccinate (<scene name='71/716528/Y01/1'>Y01</scene>) has a chemical formula of C<sub>31</sub>H<sub>50</sub>O<sub>4</sub> and has a molecular weight of 487 Da. One Y01 is attached to chain a and another Y01 is attached to chain b<ref name="twentyone">http://www.ebi.ac.uk/pdbe/entry/pdb/5c65/bound/Y01</ref>. To view Y01 in 3D use [http://www.rcsb.org/pdb/explore/jmol.do?structureId=5C65&residueNr=Y01 JSmol]. GLUT3 was also identified and analyzed in a complex with alpha & beta d-glucose. This model was reported with a resolution of 1.5 Å and was in an open-occluded state<ref name="nine"/>. The alpha and beta d glucose were coordinated in a <scene name='71/716528/Binding_pocket/8'>binding pocket</scene> by amino acids N315, E378, Q159, W368, Q280, Q281, N286. These are located on TM8 and TM10a and TM10b<ref name="nine"/>. A figure of this glucose coordination by Deng, D., et al. is available [http://www.nature.com/nature/journal/v526/n7573/fig_tab/nature14655_F2.html here]. GLUT3 structure was also determined when bound to maltose in an outward-open and an outward-occluded conformation. This was measure to a resolution of 2.6 Å and 2.4 Å respectively. A figure of this maltose coordination by Deng, D., et al. is available [http://www.nature.com/nature/journal/v526/n7573/fig_tab/nature14655_F3.html here]. To get a better view of the structure of the protein use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5C65 FirstGlance].
+
Insulin glargine is made by recombinant DNA technology with Escherichia coli <ref name="one">McKeage, K., & Goa, K. L. (2001). Insulin glargine. Drugs, 61(11), 1599-1624.</ref>. Insulin glargine was originally created by Aventis Pharmaceuticals and was accepted for use in 2000 in the USA and the EU <ref name="two">Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A., ... & Redwan, E. M. (2014). Cell factories for insulin production. Microbial cell factories, 13(1), 141.
 +
</ref>. Insulin glargine is created through the manipulation of amino acids <ref name="two">Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A., ... & Redwan, E. M. (2014). Cell factories for insulin production. Microbial cell factories, 13(1), 141.
 +
</ref>. A glycine is added to the C-terminal A-chain asparagine and two arginines are added to the C-terminal B-chain threonine <ref name="two">Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A., ... & Redwan, E. M. (2014). Cell factories for insulin production. Microbial cell factories, 13(1), 141.
 +
</ref>. The final drug product forms at a pH of 4 through the expression of E. coli and the generation of the precursor proinsulin <ref name="three">Walsh, G. (2005). Therapeutic insulins and their large-scale manufacture. Applied microbiology and biotechnology, 67(2), 151-159.
 +
</ref>
-
This is 5c65 shown with <scene name="/12/3456/Sample/1">colored groups</scene>. This is 5c65 shown as a <scene name="/12/3456/Sample/2">transparent representation</scene> of the protein.
+
== Structure ==
 +
Insulin glargine is a hormone protein consisting of 52 amino acids in an asymmetric unit. It has two unique chains, chain A and B. The structure was determined by X-ray diffraction and was measured at a resolution of 1.66 Angstroms.
 +
Chain A is 21 amino acids long and consists of two alpha helices and one beta sheet. It is modified from normal insulin by the substitution of asparagine for glycine at the twenty first amino acid of the chain. It also has an L-cystine protein modification at amino acids C6 and C11 of the chain <ref name="four">Barba de la Rosa, A. P., Lara-Gonzalez, S., Montero-Moran, G. M., Escobedo-Moratilla, A., and Perez-Urizar, J.T. Physiochemical and structural analysis of a biosimilar insulin glargine formulation and its reference. In Press.</ref>. This modification is in which a disulfide bond is formed between the side chains of two cysteine residues within the amino acid chain via an oxidation reaction <ref name="five">Gortner, R. A., & Hoffmann, W. F. (1925). l-Cystine. Organic Syntheses, 5, 39.</ref>.
 +
Chain B is 31 amino acids long and consists of two alpha helices and one beta sheet . It is modified from normal insulin by the addition of two arginine residues to the C-terminus of the chain <ref name="four">Barba de la Rosa, A. P., Lara-Gonzalez, S., Montero-Moran, G. M., Escobedo-Moratilla, A., and Perez-Urizar, J.T. Physiochemical and structural analysis of a biosimilar insulin glargine formulation and its reference. In Press.</ref><ref name="six">Agin, A., Jeandidier, N., Gasser, F., Grucker, F., and Sapin, R. (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay, Diabetes and Metabolism 33, 205-212</ref>. These modifications raise the isoelectric point (pI) from 5.4 to 6.7, improving solubility under mildly acidic conditions <ref name="seven">Bolli, G. B. & Owens, D. R. (2000). Insulin glargine. The Lancet, 356(9228), 443-445.</ref>.
 +
These two chains are held together by disulfide bonds formed between cysteine side chains on opposing chains. One disulfide bond is formed between the cysteine residues at amino acid seven of chain A and amino acid seven of chain B. Another disulfide bond is formed between the cysteine residues at amino acid 21 of chain A and amino acid 19 of chain B <ref name="six">Agin, A., Jeandidier, N., Gasser, F., Grucker, F., and Sapin, R. (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay, Diabetes and Metabolism 33, 205-212</ref>.
 +
These disulfide linkages, general structure of insulin glargine, and its sequence differences with normal human insulin are shown by a [http://www.sciencedirect.com/science/article/pii/S1262363607000523#fig1 figure] presented by Agin et. al<ref name="six">Agin, A., Jeandidier, N., Gasser, F., Grucker, F., and Sapin, R. (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay, Diabetes and Metabolism 33, 205-212</ref>.
-
==Mechanism ==
 
-
Multiple mechanistic theories have been proposed for facilitated glucose transporters. The simple carrier model was the earliest theory proposed by Widdas and contains four steps. First, the empty carrier opens to the cis side of the membrane for glucose to bind<ref name="three"/>. Then the substrate binding carrier translocates to the trans side of the membrane where it then releases glucose on that side. Last the empty carrier switches to the cis side. Multiple mechanistic theories, including the simple carrier model were proposed but all attempted to explain two key components of GLUT transporters, the asymmetry of the transport affinities and the trans-acceleration that occurs in the presence of hexose on the trans side. Trans acceleration or accelerated transport occurs when unidirectional uptake of sugar is stimulated by the presence of intracellular sugar<ref name="twelve">Naftalin RJ, Holman GD. Transport of sugars in human red cells. In: Ellory JC, Lew V, editors. \ Membrane Transport in Red Cells. New York, NY, USA: Academic Press; 1977.</ref>. After considerable research, two popular models remain for class 1 glut transporters. The two-site/fixed site transporter theory explains the asymmetry by having both substrate binding sites simultaneously available<ref name="thirteen">Carruthers, A., DeZutter, J., Ganguly, A., & Devaskar, S. U. (2009). Will the original glucose transporter isoform please stand up! American Journal of Physiology - Endocrinology and Metabolism, 297(4), E836-E848. doi:10.1152/ajpendo.00496.2009 </ref>. After glucose is bound, hexoses exchange between sites and speed the binding process. Although this method explains the asymmetry and the kinetics of class 1 glut transporters it is not known if all class 1 glut transporters undergo a trans-acceleration model<ref name="thirteen"/>. The alternating access model explains the mechanism for class 1 glut transporters that are symmetrical and follows three steps<ref name="fourteen">Jardetzky, O. (1966). Simple allosteric model for membrane pumps [27]. Nature, 211(5052), 969-970. doi:10.1038/211969a0</ref>. The transporter has a cavity for small substrates, and contains a substrate binding site. The transporter also has two different configurational openings to one cell membrane or the other. This mechanism differs from the two-site/fixed site transporter theory by assuming there is only one binding site available at a time, leading to four different conformation states. An empty outward open state, an occluded transporter state, a inward open state and finally another occluded state<ref name="fifteen">Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S. Structure and mechanism of the lactose permease of Escherichia coli. Science. 2003;301:610–615.</ref>. Trans-acceleration is only observed in a minority of class 1 glut transporters<ref name="sixteen">Caulfield MJ, Munroe PB, O’Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5:1509–1523.</ref>. GLUT3 has been proven to be dependent on trans-acceleration. This method was discovered when hexose was found to be moving against its concentration gradient<ref name="three"/>. This movement is argued to support both the two-site transporter theory and the alternating access model. Geminate exchange, named by Naftalin et al, explains this movement with the idea that hexose could exchange freely between two binding sites within the carrier<ref name="twelve"/>. While other scientists argue that hexose could move from outward to inward without glucose binding<ref name="seventeen">Vollers, S. S., & Carruthers, A. (2012). Sequence determinants of GLUT1-mediated accelerated-exchange transport: Analysis by homology-scanning mutagenesis. Journal of Biological Chemistry, 287(51), 42533-42544.doi:10.1074/jbc.M112.369587</ref>.
 
-
== Disease in Humans ==
+
== Mechanism ==
-
===Type 2 Diabetes===
+
The affinity of insulin glargine for the receptor insulin is very similar to the affinity of human insulin for insulin, and has been documented by multiple reports <ref name="eight">Ciaraldi, T. P., Carter, L., Seipke, G., Mudaliar, S., & Henry, R. R. (2001). Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. The Journal of Clinical Endocrinology & Metabolism, 86(12), 5838-5847.</ref>. Insulin glargine’s mechanism is akin to [http://proteopedia.org/wiki/index.php/Insulin human insulin’s] mechanism <ref name="one">McKeage, K., & Goa, K. L. (2001). Insulin glargine. Drugs, 61(11), 1599-1624.</ref>. It has been shown that after subcutaneous injection of glargine, it becomes metabolized into M1 (A21-Gly-insulin) and M2 (A21-Gly-des-30B-Thr-insulin); M1 has been found to be the pharmacologically active metabolite of glargine <ref name="nine">Kuerzel, G. U., Shukla, U., Scholtz, H. E.,Pretorius, S. G., Wessels, D. H., Venter, C., Potgieter, M. A., Lang, A. M., Koose, T. & Bernhardt, E. (2003). Biotransformation of insulin glargine after subcutaneous injection in healthy subjects, Current Medical Research and Opinion, 19:1, 34-40.</ref><ref name="ten">Lucidi, P., Porcellati, F., Candeloro, P., Cioli, P., Marinelli Andreoli, A., Marzotti, S., Schmidt, R., Bolli, G.B. & Fanelli, C.G. (2014). Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose response study. Nutrition, Metabolism & Cardiovascular Diseases, 24, 709-716.</ref>.
-
Higher glucose concentration, as seen in diabetics, influences GLUT expression in leukocytes. Patients with type 2 diabetes have decreased GLUT3 in granulocytes, lymphocytes, and monocytes. In addition, the level of transcripts that encode GLUT3 are reduced in diabetic patients. Decreased expression of GLUT3 and other GLUT isoforms could possibly impair immune function and increase susceptibility to infection in type 2 diabetes<ref name="four"/>.
+
-
===Alzheimer's Disease===
+
-
Alzheimer’s disease shows levels of impaired glucose uptake and metabolism, which leads to neurodegeneration via down-regulation of many other factors in the brain. GLUT3 is responsible for transporting glucose from extracellular space to neuronal tissue, specifically dendrites and axons. Decreased levels of GLUT3 in Alzheimer brain shows a positive correlation to decreased levels of N-acetylglucosamine, which is a derivative of glucose. The impaired presence of GLUT3 leads to hyperphosphorylation of the Tau protein, which normally stabilizes neuronal microtubules. Lastly there is a reduction in the transcription for factor hypoxia-inducible factor 1, which plays a role in glucose metabolism in the brain. The comparison between a normal healthy brain and an Alzheimer brain revealed that there was a 25-30% decrease in GLUT3 levels in the Alzheimer brain<ref name="eight"/>.
+
-
===Huntington’s Disease===
+
-
Huntington’s disease leads to decreased expression of GLUT3 in the plasma membrane. Increasing the expression of GLUT3 in a Huntington’s disease brain can delay the onset of the disease<ref name="ten">Vittori, A., Breda, C., Repici, M., Orth, M., Roos, R. A. C., Outeiro, T. F., . . . the REGISTRY investigators of the European Huntington's Disease Network. (2014). Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in huntington's disease. Human Molecular Genetics, 23(12), 3129-3137. doi:10.1093/hmg/ddu022</ref>. Rab11 is a protein that is involved with the regulation of transporter trafficking. It helps in the regulation of glucose transporters particularly the GLUT3 transporter. Its regulation is impaired by Huntington’s disease, which leads to the decreased cell surface expression of GLUT3 in the brain. The exact mechanism of Huntington’s disease is still unknown to this day<ref name="eleven">McClory, H., Williams, D., & Sapp, E. (2014). Glucose transporter 3 is a rab11-dependent trafficking cargo and its transport to the cell surface is reduced in neurons of CAG140 Huntington’s disease mice. Acta Neuropathol Commun, 2, 1-9.</ref>.
+
-
== 3D structure of sugar transporters ==
 
- 
-
See [[ABC transporter]]
 
 +
== Medical Use ==
 +
===Function===
 +
Insulin glargine functions as an insulin analogue, providing basal control of glycaemia for patients with Type 1 and Type 2 diabetes <ref name="one">McKeage, K., & Goa, K. L. (2001). Insulin glargine. Drugs, 61(11), 1599-1624.</ref>.The pH 4 glargine solution is subcutaneously injected to form a microprecipitate in physiological pH.The effectiveness of glargine is dampened when mixed with more neutral insulins due to resulting disruption of precipitate formation <ref name="eleven">Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004). The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharmaceutical research, 21(8), 1498-1504.</ref>. Insulin glargine’s stability allows the formed microprecipitate to be slowly administered simulating non-diabetic basal insulin secretion <ref name="seven">Bolli, G. B. & Owens, D. R. (2000). Insulin glargine. The Lancet, 356(9228), 443-445.</ref>. This enables insulin glargine to be an extended release insulin treatment administered once per day.
</StructureSection>
</StructureSection>
== References ==
== References ==
<references/>
<references/>

Revision as of 23:45, 29 March 2017

Insulin Glargine

Caption for the 3D structure blah blah

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 McKeage, K., & Goa, K. L. (2001). Insulin glargine. Drugs, 61(11), 1599-1624.
  2. 2.0 2.1 2.2 Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A., ... & Redwan, E. M. (2014). Cell factories for insulin production. Microbial cell factories, 13(1), 141.
  3. Walsh, G. (2005). Therapeutic insulins and their large-scale manufacture. Applied microbiology and biotechnology, 67(2), 151-159.
  4. 4.0 4.1 Barba de la Rosa, A. P., Lara-Gonzalez, S., Montero-Moran, G. M., Escobedo-Moratilla, A., and Perez-Urizar, J.T. Physiochemical and structural analysis of a biosimilar insulin glargine formulation and its reference. In Press.
  5. Gortner, R. A., & Hoffmann, W. F. (1925). l-Cystine. Organic Syntheses, 5, 39.
  6. 6.0 6.1 6.2 Agin, A., Jeandidier, N., Gasser, F., Grucker, F., and Sapin, R. (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay, Diabetes and Metabolism 33, 205-212
  7. 7.0 7.1 Bolli, G. B. & Owens, D. R. (2000). Insulin glargine. The Lancet, 356(9228), 443-445.
  8. Ciaraldi, T. P., Carter, L., Seipke, G., Mudaliar, S., & Henry, R. R. (2001). Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. The Journal of Clinical Endocrinology & Metabolism, 86(12), 5838-5847.
  9. Kuerzel, G. U., Shukla, U., Scholtz, H. E.,Pretorius, S. G., Wessels, D. H., Venter, C., Potgieter, M. A., Lang, A. M., Koose, T. & Bernhardt, E. (2003). Biotransformation of insulin glargine after subcutaneous injection in healthy subjects, Current Medical Research and Opinion, 19:1, 34-40.
  10. Lucidi, P., Porcellati, F., Candeloro, P., Cioli, P., Marinelli Andreoli, A., Marzotti, S., Schmidt, R., Bolli, G.B. & Fanelli, C.G. (2014). Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose response study. Nutrition, Metabolism & Cardiovascular Diseases, 24, 709-716.
  11. Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004). The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharmaceutical research, 21(8), 1498-1504.

Proteopedia Page Contributors and Editors (what is this?)

Joanna Morelli

Personal tools